Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios
Assets AverageEnterprise ValueEquity AverageEquity RatioInterest Coverage RatioInvested CapitalReturn on AssetsReturn on Capital EmployedReturn on EquityTimes Interest Earned

Acro Biomedical (ACBM) FCF Margin (2017 - 2022)

Acro Biomedical (ACBM) has 6 years of FCF Margin data on record, last reported at 2.94% in Q4 2022.

  • For Q4 2022, FCF Margin rose 718.0% year-over-year to 2.94%; the TTM value through Sep 2023 reached 3.72%, up 1830.0%, while the annual FY2022 figure was 22.4%, 4739.0% down from the prior year.
  • FCF Margin reached 2.94% in Q4 2022 per ACBM's latest filing, down from 87.82% in the prior quarter.
  • Across five years, FCF Margin topped out at 6133.31% in Q3 2019 and bottomed at 23.3% in Q2 2018.
  • Average FCF Margin over 5 years is 524.14%, with a median of 1.55% recorded in 2018.
  • The widest YoY moves for FCF Margin: up 613348bps in 2019, down -1588bps in 2019.
  • A 5-year view of FCF Margin shows it stood at 12.88% in 2018, then crashed by -123bps to 3.01% in 2019, then dropped by -26bps to 3.78% in 2020, then tumbled by -168bps to 10.12% in 2021, then surged by 71bps to 2.94% in 2022.
  • Per Business Quant database, its latest 3 readings for FCF Margin were 2.94% in Q4 2022, 87.82% in Q1 2022, and 10.12% in Q4 2021.